Nuzyra (omadacycline) / ZAI Lab, Paratek Pharmaceuticals - LARVOL DELTA

Clinical Experience with Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis. (PubMed, Infect Dis Ther) - P | "In this real-world analysis, there was no observed difference in efficacy between omadacycline and standard care for DFI, including cases complicated by AOM, with few adverse events observed. These findings support continued evaluation and potential use of omadacycline in treating select patients with DFIs."

Journal • Immunology • Infectious Disease • Inflammation • Systemic Inflammatory Response Syndrome

In Vitro Activity of Omadacycline and Eravacycline against Nocardia brasiliensis Isolates (EADV 2026) - "These next-generation tetracyclines were compared against the current standard of care and earlier generation agents, including tigecycline, minocycline, and SXT...Figure 1: Cumulative percentages of Nocardia brasiliensis clinical isolates (n = 50) inhibited by tigecycline (TGC), eravacycline (ERV), trimethoprim-sulfamethoxazole (SXT), minocycline (MIN), and omadacycline (OMC)...These agents offer a potent and feasible oral alternative to current toxic standards. Transitioning to these therapies could transform actinomycetoma from a disabling, difficult-to-manage condition into one with a streamlined, outpatient-friendly cure, addressing a major gap in the global management of neglected tropical diseases."

Preclinical • Infectious Disease

A Preventable Source of Cutaneous Mycobacterium abscessus Infection: Contaminated Insulin Syringes in a Patient with Diabetes Mellitus (EADV 2026) - "Case Presentation A 48-year-old woman with type 2 diabetes mellitus treated with insulin glargine, metformin, and weekly semaglutide presented with a two-month history of painful inflammatory lesions involving both upper extremities...Multiple empirical antibiotic regimens, including dicloxacillin, clindamycin, and ciprofloxacin, were ineffective...Broth microdilution susceptibility testing according to Clinical and Laboratory Standards Institute guidelines demonstrated susceptibility to amikacin, clarithromycin, azithromycin, tigecycline, omadacycline, and tedizolid; intermediate susceptibility to imipenem and cefoxitin; and resistance to fluoroquinolones and linezolid...Negative stains and molecular assays do not exclude the diagnosis, and prolonged mycobacterial culture remains essential. This case highlights the importance of species identification and antimicrobial susceptibility testing to guide targeted multidrug therapy."

Clinical • Aesthetic Medicine • Diabetes • Infectious Disease • Inflammation • Metabolic Disorders • Mood Disorders • Nontuberculous Mycobacterial Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

Omadacycline for Treatment Refractory Mycoplasma Genitalium Urethritis (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: Montefiore Medical Center

New P2 trial • Infectious Disease

Falling short: Inadequate target attainment in guideline-based therapy of nontuberculous mycobacterial disease. (PubMed, medRxiv) - "These include macrolides for M. abscessus and the M. avium complex (MAC), and rifampicin for M. kansasii. Bedaquiline emerged as a promising option against M. abscessus and MAC, and clofazimine against the latter, consistent with recent clinical reports. Omadacycline PTAs predict improved efficacy compared to tigecycline for patients with M. abscessus and suggest clinical utility for MAC. As is common practice for antibacterials, PTA considerations could inform NTM treatment guidelines and help select drug combinations in future trials."

Journal • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Case Report: Coinfection of influenza A and Chlamydia psittaci pneumonia. (PubMed, Front Med (Lausanne)) - "Omadacycline and baloxavir marboxil were prescribed. He was discharged and recovered on day 60 of the follow-up. This case underscores the diagnostic complexity of coinfection and the use of NGS testing in this severe condition and the role of omadacycline in psittacosis."

Journal • Acute Kidney Injury • Anorexia • Critical care • Fatigue • Hepatology • Infectious Disease • Influenza • Liver Failure • Nephrology • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases

Nitric Oxide Enhances Antimicrobial Effects of Clofazimine Against Mycobacterium abscessus (NACFC 2026) - "We also performed 3-D checkerboard assays in one laboratory strain (ATCC 19977) combining CFZ + dNO with seven antibiotics (amikacin, cefoxitin, linezolid, tedizolid, bedaquiline, omadacycline, and imipenem). Inhaled NO is a promising adjunctive therapy for MAB, particularly when combined with CFZ. However, NO-antibiotic interactions are complex, and further research is needed to guide the selection of optimal antibiotic regimens."

Cardiovascular • Infectious Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Pulmonary Actinomycosis Diagnosed via BALF mNGS in a 53-Year-Old Nonsmoking Man With Pneumoconiosis and Penicillin-Induced Thrombocytopenia: A Case Report. (PubMed, Am J Case Rep) - "Intravenous ampicillin/sulbactam led to clinical and radiologic improvement, but severe thrombocytopenia developed...After discontinuation of penicillin and joint evaluation by respiratory physicians and clinical pharmacists, omadacycline was administered, followed by oral doxycycline...CONCLUSIONS This case illustrates the diagnostic difficulty of pulmonary actinomycosis in a patient with pneumoconiosis and suggests that BALF mNGS can be helpful when routine studies are unrevealing. It also indicates that omadacycline is a feasible alternative when penicillin-associated thrombocytopenia prevents continuation of first-line therapy."

Journal • Cough • Hematological Disorders • Infectious Disease • Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Thrombocytopenia • Tuberculosis

Clinical characteristics of Chlamydia psittaci pneumonia diagnosed by next-generation sequencing: An observational study. (PubMed, Medicine (Baltimore)) - "Post-diagnosis, treatment with moxifloxacin, doxycycline, or omadacycline for 10 to 21 days yielded generally favorable outcomes. Both tNGS and mNGS are effective diagnostic tools, and tNGS provides a more cost-saving and rapid alternative. Early treatment with fluoroquinolones or tetracyclines confers significant therapeutic benefits."

Biomarker • Journal • Next-generation sequencing • Observational data • Retrospective data • Anorexia • Cardiovascular • Cough • Critical care • Heart Failure • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Musculoskeletal Pain • Pain • Pneumonia • Respiratory Diseases

Omadacycline as an alternative to macrolides within maintenance regime for Mycobacterium abscessus pulmonary disease in children with Cystic Fibrosis: Adapting pharmacotherapy in response to emerging macrolide resistance (ERS 2026) - "BACKGROUND: Mycobacterium abscessus infection in children with cystic fibrosis (CF) presents major therapeutic challenges, including inducible(erm gene) resistance to macrolide antibiotics (e.g. Azithromycin) which have bacteriostatic action and may negatively impact the bactericidal action of aminoglycosides when used in combination. Omadacycline, a novel tetracycline antibiotic with activity against non-tuberculous mycobacteria (NTM), offers an effective alternative to macrolides...Following an intensification regime of 3 weeks of intravenous cefoxitin, meropenem and amikacin, omadacycline was incorporated into maintenance therapy alongside clofazimine and nebulised amikacin... Emerging evidence of inducible resistance in M.abscessus isolates may impact success of eradication when using macrolides. Omadacycline appears to be an effective alternative to macrolides in achieving successful culture conversion when used in maintenance therapy for NTM-PD."

Clinical • Chronic Cough • Cough • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

OMADACYCLINE FOR PULMONARY NON-TB MYCOBACTERIAL INFECTIONS: A RETROSPECTIVE CASE SERIES OF CLINICAL, MICROBIOLOGIC, AND RADIOGRAPHIC OUTCOMES (CHEST 2026) - No abstract available

Retrospective data • Infectious Disease

Activity of Omadacycline and Comparators Against Common Microbial Contaminants: Cronobacter sakazakii, Pluralibacter gergoviae, and Burkholderia cepacia species complex isolates (IDWeek 2026) - No abstract available

Infectious Disease

In Vitro Activity of Omadacycline against 7,200 Bacterial Clinical Isolates Representing Multiple Infection Types from the United States (2024-2025) (IDWeek 2026) - No abstract available

Preclinical • Infectious Disease

In Vitro Activity of Omadacycline Against Borrelia spp. and Bartonella henselae (IDWeek 2026) - No abstract available

Preclinical • Infectious Disease • Lyme Disease

Mycobacterium avium Complex Pulmonary Infections Treated with Regimens Containing Omadacycline in a Veteran Population (IDWeek 2026) - No abstract available

Clinical • Infectious Disease • Tuberculosis

Omadacycline-Associated Skin Hyperpigmentation in Patients with Nontuberculous Mycobacterial Infections: A Case-Control Study (IDWeek 2026) - No abstract available

Clinical • Nontuberculous mycobacteria • Infectious Disease • Nontuberculous Mycobacterial Disease

Tooth Staining While on Prolonged Omadacycline: A Single-Center Survey (IDWeek 2026) - No abstract available

Clinical • Infectious Disease • Tuberculosis

Omadacycline-Associated Pancreatic Injury: a Spectrum from Mild Interstitial to Recrudescent Pancreatitis with Pharmacovigilance Implications. (PubMed, Infect Dis Ther) - "Omadacycline can cause a spectrum of pancreatic injury, from mild interstitial pancreatitis to recrudescent disease, with CT findings that may be unobtrusive and easily overlooked. This underrecognition likely contributes to underreporting, which may explain the absence of a FAERS pancreatitis signal. Clinicians should monitor lipase and amylase, maintain a low threshold for CT imaging when enzymes rise, and report suspected cases using specific MedDRA terms."

Adverse events • Journal • Critical care • Pancreatitis

Zebrafish larvae swim bladder serves as a model to study Mycobacterium abscessus infection kinetics, host-pathogen interactions and drug efficacy. (PubMed, Mycobacteria) - "To study drug efficacy in this model, zebrafish larvae were infected into the swim bladder with M. abscessus:eGFP, treated with clarithromycin or omadacycline by immersion and CFU counts were determined at 2- and 4-day post-treatment. Overall, this study established the first zebrafish: M. abscessus swim bladder infection model to study localized NTM infection, host-pathogen interactions, and drug efficacy studies."

Journal • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • TNFA

Early diagnosis and therapy of Chlamydia psittaci pneumonia: insights from chest CT, tNGS, and omadacycline in 34 cases. (PubMed, Front Med (Lausanne)) - "Subpleural consolidation and the reverse halo sign on chest imaging may provide important diagnostic clues. BALF tNGS is valuable for the early identification of C. psittaci infection, and omadacycline may be an effective therapeutic option, particularly in patients with persistent fever after quinolone therapy."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases • CRP

Advances in the diagnosis and management of skin and soft tissue infections. (PubMed, BMJ) - "Management of SSTI includes antibiotics such as penicillin VK, dicloxacillin, or a cephalosporin, while treatment for skin abscess includes incision and drainage, with antibiotics recommended in select patients. While most patients with cellulitis or skin abscess are appropriate for discharge with follow-up, patients with sepsis and those with challenges adhering to therapy, immunosuppression, or failed outpatient therapy should be referred to the emergency department. Novel antibiotics such as tedizolid, delafloxacin, omadacycline, and ceftaroline may be considered in select cases."

Journal • Review • Dermatology • Infectious Disease • Inflammation • Pain • Septic Shock

Non-invasive management of severe chlamydia psittaci pneumonia presenting with hypoxemia and diarrhea: a case report. (PubMed, Front Med (Lausanne)) - "Comprehensive non-invasive multidisciplinary management was implemented throughout the disease course, including high-flow nasal cannula (HFNC) oxygen therapy, dual anti-infective therapy with omadacycline combined with levofloxacin, symptomatic supportive care, and standardized stepwise early rehabilitation training. It highlights that severe psittacosis pneumonia can present with atypical dominant manifestations of combined hypoxemia and severe gastrointestinal diarrhea, which is easily misdiagnosed clinically. Targeted mNGS enables rapid etiological confirmation of atypical severe psittacosis, and individualized non-invasive integrated management can achieve favorable prognosis in eligible critically ill patients, providing a valuable clinical reference for the standardized diagnosis and treatment of similar rare cases."

Journal • Infectious Disease • Lumbar Back Pain • Pneumonia • Pulmonary Disease • Respiratory Diseases • CRP • IL6

Clinical Evaluation of Omadacycline for Pulmonary Mycobacterium abscessus Complex Infections: A Subgroup Analysis With a Focus on Macrolide Resistance. (PubMed, CHEST Pulm) - "These findings support its potential role as a tolerable and effective oral agent within multidrug regimens. Prospective studies are needed to confirm these results and define optimal use strategies."

Journal • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases

Risk factors associated with clinical failure and mortality in Chinese adult patients with community-acquired pneumonia treated with omadacycline: a real-world study. (PubMed, J Glob Antimicrob Resist) - "Omadacycline was effective and safe for CAP treatment in real-world practice, including elderly and comorbid patients."

Journal • Real-world evidence • Infectious Disease • Pneumonia • Respiratory Diseases

Efficacy and safety of Omadacycline in community-acquired pneumonia among elderly patients: a real-world evidence study. (PubMed, Front Cell Infect Microbiol) - "This study aimed to evaluate real-world effectiveness and safety of omadacycline for elderly community-acquired pneumonia (CAP) versus tigecycline, moxifloxacin, and cefoperazone-sulbactam after inverse probability of treatment weighting (IPTW). Antibiotic duration was comparable to tigecycline, shorter than cefoperazone-sulbactam, but longer than moxifloxacin. Given the broad pragmatic endpoint, high baseline response rate, sensitivity to endpoint definition and missing-data handling, incomplete microbiological follow-up, and residual confounding inherent to retrospective data, these findings should be interpreted as exploratory and require prospective validation."

HEOR • Journal • Real-world evidence • Retrospective data • Infectious Disease • Pneumonia • Respiratory Diseases